| Objective (1) traditional Chinese medicine huangqi injection joint FOLFOX4observation of chemotherapy for colorectal cancer patients for clinical treatment effect and the reaction and toxicity of the difference, this paper discusses the injection of astragalus joint FOLFOX4colorectal cancer treatment effect of traditional Chinese medicine and the reduction of the clinical value of poison.,(2) to understand FOLFOX4scheme in colorectal cancer treatment process to an adverse reaction to the astragalus injection and quality of life, the effects of the traditional Chinese medicine for astragalus injection "time treatment" provides an objective basis, and the Chinese traditional medicine treatment of tumor time learn provided the basis of further research。Methods In January2009to January PuAi in wuhan city hospital in90cases of oncology at colorectal cancer patients for clinical analysis, all patients confirmed by pathology for Ⅱ period (with risk factors), Ⅲ, Ⅳ issue of colorectal cancer patients. The patients were randomly divided into three groups:chemotherapy treatment group before huangqi (in a routine FOLFOX4chemotherapy for astragalus before give injection); After chemotherapy astragalus treatment group (in a routine FOLFOX4after chemotherapy for astragalus injection given); The pure chemotherapy group (use FOLFOX4 chemotherapy for astragalus give give injection). At least2cycle therapeutic evaluation, evaluation once every two cycle, observed adverse reaction (including gastrointestinal reaction and peripheral nervous system symptoms) and the quality of life (including KPS score, hemoglobin value change)。Result The pure chemotherapy group a total of24patients (80.00%) in gastrointestinal reaction in which Ⅰ～Ⅱ degrees for16cases (53.33%), Ⅲ degrees for6patients (20.00%), IV degrees for2cases (6.67%). Before chemotherapy treatment group, there were12astragalus cases (40.00%) in gastrointestinal reaction in which Ⅰ～Ⅱ degrees for9cases (30.00%), Ⅲ degrees for2cases (6.67%), IV degrees in1case (3.33%). After chemotherapy treatment group of17cases of astragalus (56.67%) in gastrointestinal reaction in which Ⅰ～Ⅱ degrees for12cases (40.00%), Ⅲ degrees for4cases (13.33%), Ⅳ degrees in1case (3.33%). In the two cycle after chemotherapy, chemotherapy treatment group, and chemotherapy before astragalus after treatment group respectively with the simple astragalus chemotherapy group comparison, gastrointestinal reaction was not statistically significant difference (P>0.05). The fourth cycle after chemotherapy, chemotherapy treatment group, and chemotherapy before astragalus after treatment group respectively with the simple astragalus chemotherapy group comparing statistical significance (P<0.05), but before chemotherapy treatment group and astragalus after chemotherapy treatment group differences between astragalus was not statistically significant (P>0.05).6cycle, chemotherapy treatment group, and chemotherapy before astragalus after treatment group respectively with the simple astragalus chemotherapy group comparing statistical significance (P<0.05); Before chemotherapy treatment group and astragalus after chemotherapy treatment group differences between astragalus was statistically significant (P<0.05)。The pure chemotherapy group, there are26patients (86.67%) in neural adverse reaction, which Ⅰ～Ⅱ degrees for18cases (60.00%), Ⅲ degrees for6patients (20.00%), Ⅳ degrees for2cases (6.67%). Before chemotherapy treatment group of17cases of astragalus (56.67%) in neural adverse reaction, which Ⅰ～Ⅱ degrees for14cases (46.67%), Ⅲ degrees for2cases (6.67%), Ⅳ degrees in1case (3.33%). Chemotherapy treatment group after a total of22cases of astragalus (73.33%) in neural adverse reaction,, of which Ⅰ～Ⅱ degrees for16cases (53.33%), Ⅲ degrees for5patients (16.67%), Ⅳ degrees in1case (3.33%). In the two cycle after chemotherapy, chemotherapy treatment group, and chemotherapy before astragalus after treatment group respectively with the simple astragalus chemotherapy group comparison, neural adverse reaction is statistically significant difference (P<0.05). Before chemotherapy treatment group and astragalus after chemotherapy treatment group differences between astragalus was not statistically significant (P>0.05). In4,6cycle after cycle, chemotherapy treatment group, and chemotherapy before astragalus after treatment group respectively with the simple astragalus chemotherapy group comparison, neural adverse reaction is statistically significant difference (P<0.05). Before chemotherapy treatment group and astragalus after chemotherapy treatment group differences between astragalus was statistically significant (P<0.05)。2cycle, the pure chemotherapy group KPS score of75.15±6.56; Before chemotherapy treatment group KPS astragalus score of85.83±6.85; After chemotherapy treatment group KPS astragalus score of80.13±6.41.4cycle, the pure chemotherapy group KPS score of74.15±6.56; Before chemotherapy treatment group KPS astragalus score of84.53±6.65; After chemotherapy treatment group KPS astragalus score of80.63±6.71.6cycle, the pure chemotherapy group KPS score of71.85±7.56; Before chemotherapy treatment group KPS astragalus score of83.53±6.85; After chemotherapy treatment group KPS astragalus score of78.63+6.41. In the second period,4cycle,6end of cycle before chemotherapy treatment group, and chemotherapy astragalus after treatment group respectively with the simple astragalus chemotherapy group comparison, KPS ratings are statistically significant difference (P<0.05). Chemotherapy treatment group, and chemotherapy before astragalus after treatment group differences between astragalus are statistically significant (P<0.05)。Chemotherapy treatment group, and chemotherapy before astragalus after treatment group respectively with the simple astragalus chemotherapy group comparison,1-6cycle before and after chemotherapy are significant anemia rate difference (P<0.05), before chemotherapy treatment group and astragalus after chemotherapy treatment group of astragalus between1～6cycle anemia rate no significant difference (P>0.05)。Conclusion (1) in patients with colorectal cancer conventional FOLFOX4scheme based on the chemotherapy combined with huangqi injection and can’t improve the curative effect, but can reduce nausea and vomiting, reducing gastrointestinal reaction of peripheral nerve response, improve patient KPS score, and the prevention and treatment of the correlation between chemotherapy anemia happen。(2) astragalus injection is used after chemotherapy before chemotherapy can reduce nausea and vomiting gastrointestinal reaction, to reduce the adverse reaction of peripheral nerve, improve patient KPS score, but does not reduce the incidence of correlation between chemotherapy anemia. The TCM huangqi injection timing can significantly reduce drug FOLFOX4plan related adverse reaction and improve the chemotherapy for colorectal cancer patients was born。... |
PDF Full Text Request